Trials / Unknown
UnknownNCT03217448
The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis
The Efficacy and Safety of Dabigatran Etexilate Comparing With Warfarin for the Anticoagulation Treatment of Cerebral Venous Thrombosis :a Pilot Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, prospective, randomized (1:1), open-label study with two parallel groups. This study is planned to investigate the efficacy and safety of dabigatran etexilate comparing with warfarin for the treatment of cerebral venous thrombosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran etexilate | Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization. |
| DRUG | Warfarin | Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment. |
Timeline
- Start date
- 2017-10-30
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2017-07-14
- Last updated
- 2017-11-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03217448. Inclusion in this directory is not an endorsement.